186P Exploratory pooled safety analysis of trastuzumab deruxtecan (T-DXd) in patients With HER2+ or HER2-low unresectable and/or metastatic breast cancer (mBC) in DESTINY-Breast trials

Y.H. Park, W. Jacot, S.A. Hurvitz, S. Modi, T. Yamashita, B. Xu, E. Tokunaga, X. Wang,K.S. Lee, H. Iwata, I. Krop, F. André, N. Harbeck,H.S. Rugo, E. Mathias, W.T. Pasteiner, M. Karnoub, S. Ashfaque,Y. Cheng,S-B. Kim

ESMO Open（2024）

引用 0|浏览0